Avant Institute receives grant to screen for Alzheimer’s disease
Click Here to Manage Email Alerts
Avant Institute received a grant from Davos Alzheimer’s Collaborative to perform cognitive screening at pharmacies in rural and underserved communities nationwide, according to a press release.
Avant will be partnering with Cognivue on a project that involves implementing the cognitive performance screening tool, Cognivue Clarity, in 20 to 30 Community Pharmacy Enhanced Services Network pharmacy sites across the U.S. to increase access to digital screening.
“The Cognivue Clarity is a 10-minute, self-administered computerized test of cognitive function,” Susan Lutz, Cognivue vice president of market access, told Healio. “The patient is comfortably seated in front of the Cognivue Clarity device, which is similar in size to a laptop, and watches an introductory video prior to taking the test.”
“We look forward to providing training and education for pharmacy sites to meet the needs of high‐risk communities for dementia and Alzheimer's disease,” Amina Abubakar, PharmD, AAHIVP, president of Avant Institute and Avant Pharmacy and Wellness Center CEO, said in the press release. “This grant provides an opportunity to address a significant need to fill the gaps in conducting standardized cognitive assessments for patients, and pharmacies provide an access point to reach underserved and rural communities. We are proud to be partnering with the Davos Alzheimer’s Collaborative on this initiative to address patient care needs and advance the collaboration between community pharmacies and their local providers.”
Avant Institute now enters a global network of 12 grant projects funded by the Davos Alzheimer’s Collaborative Healthcare System Preparedness Project, according to the release.